AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection

Published: 29 October 2024

  • Views:

    Views Icon 2109

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.

  • To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
  • Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
  • Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
  • Don't miss the key take aways from our Highlights series.

More from this programme

Part 1

View From the Thoraxcenter

1 session
View from the Thoraxcenter: AHA 24 Late-breaking Preview Watch now

Part 2

Late-Breaker Discussions with Dr Harriette Van Spall

5 sessions
ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS Watch now
NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI Watch now
SUMMIT: Tirzepatide in Patients with HFpEF and Obesity Watch now
FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk Watch now
REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone Watch now

Part 3

Expert Interviews

14 sessions
LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD Watch now
LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia Watch now
Mavacamten: Real-World Experience from 22 Months of the REMS Program Watch now
VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy Watch now
EMPEROR-Preserved: Diastolic Dysfunction and Empagliflozin in Heart Failure Watch now
Amulet IDE: The AMPLATZER Amulet Left Atrial Appendage Occluder Five-Year Results Watch now
NTLA-2001 in Patients with Transthyretin Amyloidosis with Cardiomyopathy Watch now
SELECT: Semaglutide in Obese and Overweight Patients with a History of Coronary Artery Bypass Surgery Watch now
ENDEAVOR: Myeloperoxidase Inhibition with Mitiperstat in HFpEF Watch now
New Insights from CLEAR OUTCOMES: Bempedoic Acid in Statin-Intolerant Patients with PAD Watch now
ALPACAR: Phase 2 Trial of Zerlasiran in High Risk Patients Watch now
BROOKLYN: Safety and Efficacy of Obicetrapib in Patients with HeFH Watch now
KRAKEN: Phase 2 Trial of Muvalaplin in High Risk Patients Watch now
OPTION: LAA Closure with Oral Anticoagulation after AF Ablation Watch now

Part 4

Highlights

1 session
3 Trials That Will Change My Practice with Dr Michelle Kittleson Watch now

About the episode

AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD). 

 

Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).

 

CLEAR OUTCOMES is a double-blind, randomized, placebo-controlled trial, where statin-intolerant patients who have or are at high risk for cardiovascular disease, including PAD, received once-daily tablets of either bempedoic acid or placebo. 13,970 patients were enrolled in the trial and were followed-up for a duration of 68 months. The primary outcome measure was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke or coronary revascularization. 

 

Interview Questions:
1.    What is the reasoning behind the CLEAR OUTCOMES trial?
2.    Could you tell us about the mechanism of action behind bempedoic acid?
3.    What was the study design and patient population?
4.    What were the key findings?
5.    What are the take-home messages for practice?
6.    What further research is needed in this area?

 

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.

Faculty Biographies

Marc P Bonaca

Marc P Bonaca

Director of Vascular Research and an Associate Professor of Medicine

Dr Marc Bonaca is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health which is an Academic Research Organization created by and affiliated with the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research. CPC is a core resource of the University of Colorado research and community outreach infrastructure.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. Following his medical residency training, he completed a fellowship in cardiology and a fellowship in vascular medicine at Brigham and Women’s…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.